Should You Invest in Coherus BioSciences (CHRS)?

Scout Investments, an affiliate of Carillon Tower Advisers, an investment management company, released its “Carillon Scout Small Cap Fund” third quarter 2022 investor letter. You can download a copy of the same here. The fund underperformed in the quarter relative to its Russell 2000 Growth Index benchmark. Macroeconomic headwinds affected the performance of the fund in the quarter. As per the letter, investors prefer growth stocks to value stocks, as small-cap growth stocks outperformed small-cap value stocks during the quarter. In addition, you can check the top 5 holdings of the fund to know its best picks in 2022.

Carillon Tower Advisers highlighted stocks like Coherus BioSciences, Inc. (NASDAQ:CHRS) in its Q3 2022 investor letter. Headquartered in Redwood City, California, Coherus BioSciences, Inc. (NASDAQ:CHRS) is a biopharmaceutical company. On December 30, 2022, Coherus BioSciences, Inc. (NASDAQ:CHRS) stock closed at $7.92 per share. One-month return of Coherus BioSciences, Inc. (NASDAQ:CHRS) was 17.51%, and its shares lost 51.74% of their value over the last 52 weeks. Coherus BioSciences, Inc. (NASDAQ:CHRS) has a market capitalization of $616.001 million.

Carillon Tower Advisers made the following comment about Coherus BioSciences, Inc. (NASDAQ:CHRS) in its Q3 2022 investor letter:

Coherus BioSciences, Inc. (NASDAQ:CHRS) is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of immunotherapies to treat cancer. The company’s stock reacted positively to the approval of its biosimilar CimerliTM to treat retinal disease.”

Coherus BioSciences, Inc. (NASDAQ:CHRS) is not on our 30 Most Popular Stocks Among Hedge Funds list. As per our database, 20 hedge fund portfolios held Coherus BioSciences, Inc. (NASDAQ:CHRS) at the end of the third quarter, which was 23 in the previous quarter.

We discussed Coherus BioSciences, Inc. (NASDAQ:CHRS) in another article and shared Carillon Tower Advisers’ views on the company. In addition, please check out our hedge fund investor letters Q3 2022 page for more investor letters from hedge funds and other leading investors.

Suggested Articles:

Disclosure: None. This article is originally published at Insider Monkey.